%0 Journal Article
%T The Introduction of Bedaquiline Regimen for Drug-Resistant Tuberculosis in the Philippines: An Operational Study
%A Vincent M. Balanag Jr.
%A Vivian S. Lofranco
%A Mariquita J. Mantala
%A Mary Rosary T. Santiago
%A Patrice Jamie E. Cabasis
%A Arnyl G. Araneta
%A Anna Marie Celina G. Garfin
%J Journal of Tuberculosis Research
%P 205-219
%@ 2329-8448
%D 2022
%I Scientific Research Publishing
%R 10.4236/jtr.2022.104016
%X <span style=\"font-family:Verdana;\"><b><span style=\"font-family:Verdana;\">Objectives:</span></b></span><span><span><span style=\"font-family:&quot;\"><span style=\"font-family:Verdana;\"> Bedaquiline (BDQ) is the first new anti-tuberculosis (TB) drug
introduced to the market after 45 years. Recent studies have shown the
potential benefits of adding bedaquiline to regimens for drug-resistant TB
(DR-TB). In search of more effective regimens for DR-TB, bedaquiline was
introduced in the TB program in the Philippines under operational research to
assess its effectiveness, safety, and tolerability when given with background
regimens among patients with multi-or extensively DR-TB (MDR/XDR-TB). </span><b><span style=\"font-family:Verdana;\">Design:</span></b><span style=\"font-family:Verdana;\"> A prospective cohort study of patients with MDR/XDR-TB was given with a
bedaquiline-containing regimen from June 2016 to May 2017. Demographic data,
presence of comorbidities, and microbiologic profile on entry were recorded.
Bedaquiline was administered at the recommended dose of 400 mg once daily for
14 days, then 200 mg three times a week for 22 weeks together with World Health
Organization (WHO)-compliant background regimen. The time to culture
conversion, interim outcomes at the 6th month of treatment, end-of-treatment
outcomes, and post-treatment follow-up outcomes after one year was determined.
The frequency and severity of adverse events (SAE) were recorded as part of
pharmacovigilance. </span><b><span style=\"font-family:Verdana;\">Results:</span></b><span style=\"font-family:Verdana;\"> Seventy-five patients were given with
bedaquiline-containing regimen during the study period. Forty-two (56.0%) had
second-line injectable resistance, 23 (30.7%) had fluoroquinolone-resistance, 6
(8.0%) had MDR-TB, and 4 (5.3%) </span><span style=\"font-family:Verdana;\">had XDR-TB. </span></span></span></span><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\">In</span></span></span><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"> the 6th month of post-enrolment, 79% were
culture-negative</span></span></span><span><span><span style=\"font-family:&quot;\"><span style=\"font-family:Verdana;\">. The treatment success rate was 65.3% (37 were
cured and 12 completed treatment), 7 (9.3%) died, 17 (22.7%) lost to follow-up,
and 2 (2.7%) were withdrawn from treatment. Adverse events included vomiting
(80%), dizziness (69%), nausea (52%), cough (44%), and headache
%K Bedaquiline
%K Drug-Resistant TB
%K XDR-TB
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=121738